In this era of pharmaceutical and technological advancements, gaining insights into prevalent insulin administration practices under real-life conditions becomes pivotal for healthcare professionals. The investigators aim to explore insulin injection habits through an online survey among a broad, unselected group of participants with type 1 and type 2 diabetes undergoing daily prandial and/or basal insulin treatment. Eligible participants will access and complete the survey at their convenience after providing online informed consent within the study period
HYPOTHESIS The study hypothesis posits that there is significant variability in the practices of insulin administration among patients with diabetes using daily insulin injections. This diversity in administration practices may have a notable impact on the overall efficacy of treatment regimens and the successful management of the disease, thereby emphasizing the need for a comprehensive understanding of these practices to enhance patient outcomes and optimize diabetes care. OBJECTIVES The main objective of the study is to comprehensively assess and characterize the diverse insulin administration practices among individuals with diabetes using injections, focusing on both prandial and basal insulin. By employing an online survey methodology and targeting a broad demographic through a diabetes information platform Canal Diabetes, the investigators aim to gain valuable insights into the variability, challenges, and overall patterns of insulin administration. The findings will contribute to a better understanding of real-world practices, facilitating improvements in patient guidance and optimizing diabetes care strategies. STUDY DESIGN The study follows a cross-sectional observational design, allowing the investigators to capture a snapshot of the current insulin administration practices via an online questionnaire among the diverse population of diabetes patients using multiple insulin injections. STUDY PROCEDURE AND SCHEDULE The study, focusing on insulin administration practices among participants with diabetes using multiple insulin injections, will employ a two-month online survey accessible on the designated online platform Canal Diabetes. Recruitment efforts through the diabetes information platform Canal Diabetes will inform eligible participants about the study's voluntary nature, emphasizing response confidentiality. Participants meeting the criteria, will access and complete the online informed consent and survey at their convenience within the designated two-month period. Post-survey, collected data will be securely stored and anonymized for subsequent analysis. STUDY DURATION The anticipated duration of this study will be 4 months, with subject recruitment set to begin in July 2024 and aiming for the completion of statistical analysis by the 31st of October 2024. GOOD CLINICAL PRACTICE The procedures set out in this study protocol, pertaining to the conduct, evaluation, and documentation of this study, are designed to ensure that the sponsor and investigator (in this case the same person) comply with the principle of the good clinical practice guidelines and the Declaration of Helsinki in the conduct, evaluation and documentation of this study. The study will also be carried out in keeping with local legal requirements. SUBJECTS INFORMATION AND INFORMED CONSENT Prior to taking the online questionnaire, participants will be required to provide explicit consent to participate in the study. An online informed consent document, encompassing details about the study and the consent form, will be prepared and supplied to participants. This document will be presented in a language accessible to participants, and clear contact information will be provided for any questions that may arise. ENSURING DATA CONFIDENTIALITY The study database will not contain any information that could allow the individual identification of the study participants. The data obtained will be used exclusively for the purposes described in this research project. The information will be treated as confidential and will be stored and processed in accordance with the provisions of EU Regulation 2016/679 of the European Parliament and the Council of 27 April 2016 on the protection of personal data and the free movement of such data, as well as Organic Law 3/2018 of December.
INCLIVA
Valencia, Spain
Number of total insulin injections
Number of total insulin injections per day
Time frame: through study completion, an average of 16 weeks
Number of prandial insulin injections
Number of prandial insulin injections per day
Time frame: through study completion, an average of 16 weeks
Number of basal insulin injections
Number of basal insulin injections per day
Time frame: through study completion, an average of 16 weeks
Timing of prandial insulin injection
Timing of prandial insulin injection: before meals, during meals, after meals, or at some point during the day
Time frame: through study completion, an average of 16 weeks
Time interval before prandial insulin injection
If insulin administration occurs before starting the meal: time interval (minutes)
Time frame: through study completion, an average of 16 weeks
Time interval after prandial insulin injection
If insulin administration occurs after the meal: time interval (minutes)
Time frame: through study completion, an average of 16 weeks
Insulin overdosing
Insulin overdosing when correcting abnormal glucose values (Y/N)
Time frame: through study completion, an average of 16 weeks
Insulin underdosing
Insulin overdosing when correcting abnormal glucose values (Y/N)
Time frame: through study completion, an average of 16 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Study Type
OBSERVATIONAL
Enrollment
400
Insulin administration site
Insulin administration site: abdomen, thigh, arm
Time frame: through study completion, an average of 16 weeks
Site rotation
Injection site rotation: (Yes/No)
Time frame: through study completion, an average of 16 weeks
Change of the insulin needle
Frequency in the change of the insulin needle
Time frame: through study completion, an average of 16 weeks
Use of smart pens
Use of smart pens (Y/N)
Time frame: through study completion, an average of 16 weeks
Type of prandial insulin
Type of prandial insulin used
Time frame: through study completion, an average of 16 weeks
Daily dose of prandial insulin
Daily dose of prandial insulin (IU/kg)
Time frame: through study completion, an average of 16 weeks
Type of basal insulin
Type of basal insulin used
Time frame: through study completion, an average of 16 weeks
Daily dose of basal insulin
Daily dose of basal insulin (IU/kg)
Time frame: through study completion, an average of 16 weeks
Last HbA1c
Last HbA1c value
Time frame: through study completion, an average of 16 weeks
Date of last HbA1c
Date of last HbA1c value
Time frame: through study completion, an average of 16 weeks
Diabetic ketoacidosis
Diabetic ketoacidosis (DKA) in the last year (Y/N)
Time frame: through study completion, an average of 16 weeks
Hypoglycemic episodes
Severe hypoglycemic episodes in the last year (Y/N)
Time frame: through study completion, an average of 16 weeks
Hyperglycemic episodes
Hyperglycemic episodes with medical support in the last year (Y/N)
Time frame: through study completion, an average of 16 weeks
Age of diabetes onset
Age of diabetes onset (years/months)
Time frame: through study completion, an average of 16 weeks
Self-monitoring of capillary glucose
Self-monitoring of capillary blood glucose (SMBG) (Y/N)
Time frame: through study completion, an average of 16 weeks
Glucose monitoring in real-time or intermittently scanned
Continuous glucose monitoring (CGM) in real-time or intermittently scanned (Y/N)
Time frame: through study completion, an average of 16 weeks
Lack of daily glucose monitoring
Lack of daily glucose monitoring (Y/N)
Time frame: through study completion, an average of 16 weeks
Lack of correction based on glucose values
Lack of correction based on glucose values (Y/N)
Time frame: through study completion, an average of 16 weeks
Time in Range (%TIR)
If CGM user, CGM parameters from the last 28 days: Time in Range (%TIR)
Time frame: through study completion, an average of 16 weeks
Time Below Range (%TbR)
If CGM user, CGM parameters from the last 28 days: Time Below Range (%TbR)
Time frame: through study completion, an average of 16 weeks
Time Above Range (%TaR)
If CGM user, CGM parameters from the last 28 days: Time Above Range (%TaR)
Time frame: through study completion, an average of 16 weeks
Mean glucose (mg/dL)
If CGM user, CGM parameters from the last 28 days: mean glucose (mg/dL)
Time frame: through study completion, an average of 16 weeks
Coefficient of variation of continuous glucose sensor values (CV)
If CGM user, CGM parameters from the last 28 days: coefficient of variation of continuous glucose sensor values (CV)
Time frame: through study completion, an average of 16 weeks